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Background: Left atrial (LA) size is a predictor of cardiovascular outcomes in patients in sinus rhythm, whereas
conflicting results have been found in atrial fibrillation (AF). This study aims to: (1) Evaluate the accuracy of LA size
to identify surrogate markers of an increased thromboembolic risk in patients with AF; (2) Assess the best method
to evaluate LA size in this setting.
Methods: Cross-sectional study enrolling 500 consecutive patients undergoing transthoracic and transesophageal
echocardiography evaluation during a non-valvular AF episode. LA size was measured on transthoracic echocardiography
using several methods: anteroposterior diameter, area in four-chamber view, and volumes by the ellipsoid, single- and
biplane area-length formulas. Surrogate markers of stroke were evaluated by transesophageal echocardiography: LA
appendage (LAA) thrombus, LAA low flow velocities, dense spontaneous echocardiographic contrast and LA abnormality.
Results: Except for non-indexed anteroposterior diameter, increased LA size quantified by all the other methods showed
a moderate to high discriminatory power to identify all the surrogate markers of stroke. A higher accuracy was observed
for indexed LA area in four-chamber view (LAA thrombus: AUC = 0.708, CI95% 0.644- 0.772, p<0.001; LAA low flow
velocities: AUC = 0.733, CI95% 0.674- 0.793, p<0.001; dense spontaneous echocardiographic contrast: AUC = 0.693, CI95%
0.638- 0.748, p<0.001; LA abnormality: AUC = 0.705, CI95% 0.654-0.755, p<0.001), indexed single-plane area-length volume
(LAA thrombus: AUC = 0.701, CI95% 0.633-0.770, p<0.001; LAA low flow velocities: AUC = 0.726, CI95% 0.660-0.792, p<0.001;
dense spontaneous echocardiographic contrast: AUC = 0.673, CI95% 0.611-0.736, p<0.001; LA abnormality: AUC = 0.687,
CI95% 0.629-0.744, p<0.001), and indexed biplane area-length volume (LAA thrombus: AUC = 0.707, CI95% 0.626-0.788,
p<0.001; LAA low flow velocities: AUC = 0.737, CI95% 0.664-0.810, p<0.001; dense spontaneous echocardiographic
contrast: AUC = 0.651, CI95% 0.578-0.724, p<0.001; LA abnormality: AUC = 0.683, CI95% 0.617-0.749, p<0.001), without
significant difference between them. Indexed LA area in four-chamber view and indexed area-length volumes also were
independent predictors of surrogate markers of stroke.
Conclusions: Left atrium enlargement is associated with an increased prevalence of surrogate markers of stroke in
patients with non-valvular AF. Indexed LA area in four-chamber view and indexed area-length volumes displayed the
strongest association.* Correspondence: anacatarina.faustino@gmail.com
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Left atrium (LA) dilation has been associated with
adverse cardiovascular outcomes in patients with sinus
rhythm [1-5]. Among patients with atrial fibrillation
(AF), LA enlargement has been suggested as predictor of
stroke in some studies [6-11], while others have shown
conflicting results [12].
Most investigations regarding the prognostic impact of
LA size relied on the antero-posterior diameter measured
by M-mode (LA AP diameter). However, this method is
based in several geometric assumptions that often result
in LA size underestimation [11-16]. Thus, LA areas and
volumes derived from two-dimensional transthoracic
echocardiography (TTE) seem to provide a more accurate
assessment of LA size [17-19].
Transesophageal echocardiography (TEE) allows the as-
sessment of parameters associated with stroke, throm-
boembolism and adverse prognosis, notably the presence
of thrombus in the LA appendage (LAA thrombus) [20],
spontaneous echocardiographic contrast (SEC) [20,21],
low LA appendage flow velocities (low LAA velocities)
[22-25]. The best method to assess the relationship bet-
ween LA size and the aforementioned LA abnormalities
on TEE has never been evaluated.
This study aims to evaluate the accuracy of LA size to
identify surrogate TEE markers of an increased risk of
stroke (LAA thrombus, low LAA velocities and dense
SEC), and also to assess the best method to evaluate LA
size in this setting.
Methods
Study design
Cross-sectional study enrolling patients undergoing TTE
and TEE during a non-valvular AF episode. LA size was
measured on TTE by several methods (LA AP diameter,
LA area and LA volumes). Surrogate markers of stroke
were evaluated by TEE: LAA thrombus, low LAA velo-
cities, dense SEC, and LA ABN. ROC curve analysis was
performed to assess the accuracy of the different LA mea-
surements to identify surrogate markers of stroke. All pa-
tients provided informed consent for echocardiographic
evaluation. The study protocol was approved by Comissão
de Ética da Faculdade de Medicina da Universidade de
Coimbra (Ref 5/2013 ).
Patients and eligibility criteria
Five hundred consecutive adult patients undergoing
TTE and TEE during symptomatic episode of non-
valvular AF were enrolled during a 36-month period. AF
was identified by an electrocardiogram or endocardial
electrograms (in patients with pacemakers or implan-
table cardioverter defibrillators). Exclusion criteria were
moderate or severe mitral stenosis, severe mitral regurgi-
tation, severe aortic stenosis prosthetic mitral or aorticvalves, patients with unsuitable images for accurate
assessment of TTE measurements or TEE surrogate
markers of stroke, or any contraindication to TEE. Most
patients had an echocardiogram performed as part of
evaluation before electrical cardioversion (n = 466, 93.2%);
in the remaining patients, it was conducted for mitral
valve disease assessment (n = 14; 2.8%) and stroke eva-
luation (n = 20; 4%).
Initial data collection
Demographic, anthropometric, clinical, laboratory, ad-
ditional echocardiographic and medication data were
retrieved from clinical records (outpatient clinic evalu-
ations, emergency department, and hospital-ward ad-
missions). Discharge primary and secondary diagnoses
were recorded according to the ICD-10 (international
classification of diseases, 10th revision). Duration of AF
episode was estimated according to the patients’ com-
plaints, previously available clinical records and ECG.
In patients with pacemakers and implantable cardiover-
ter defibrillators device interrogation was performed in
order to estimate the duration of the episode. The
CHADS2 [26] and CHA2DS2-VASc [27] scores, glom-
erular filtration rate (MDRD formula), body mass index
and body surface area were calculated for all partici-
pants. Laboratory tests were performed within 24 hours
of hospital admission for patients undergoing TEE in
the emergency department and in the month preceding
the transesophageal echocardiographic examination for
participants undergoing elective TEE. Patients were
thought to have congestive heart failure whenever con-
cordant signs or symptoms were registered in their med-
ical records. Vascular disease was defined by the presence
of at least one of the following: previous myocardial infarc-
tion, peripheral artery disease or complex aortic plaque.
Echocardiographic data acquisition
All patients underwent a comprehensive imaging and
Doppler echocardiographic examination using a commer-
cially available system (Vivid 7 Dimension, GE Healthcare,
Horten, Norway) according to our laboratory protocol.
Examinations were performed by three trained trans-
thoracic and transoesophageal echocardiographers, the
images were stored on digital media for subsequent ana-
lysis using the commercially available software EchoPac
Dimension PC version 108.1.4, GE Health Care, and were
reviewed by two investigators.
M-mode and two-dimensional transthoracic images
were acquired using a M4S probe (1.5–4.0 MHz), and
were used to obtain the following LA measurements:
LA AP diameter, LA area from 4-chamber view (4C),
and LA volumes by the ellipsoid, single plane (1P) area-
length and biplane (2P) area-length methods. These
measurements were obtained at end-ventricular systole,
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opening, as shown in Figure 1. LA AP diameter (D1)
was measured by M-mode from the parasternal long-
axis view. LA area was measured using planimetry in
TTE apical four-chamber and two chamber view. LA
ellipsoid volume was calculated using AP (D1), medial–
lateral (D2) and superior–inferior (D3) LA diameters
(Figure 1) and the formula: 4/3π*(D1/2) * (D2/2) * (D3/2).
LA 1P area-length volume was obtained through the for-
mula 8/3π*A12/D3, where A1 represents the area and D3
the superior-inferior LA diameter measured from apical
4C view. LA 2P area-length volume was achieved with the
formula 8/3 π*[(A1) * (A2)/L], where A2 represent the LA
area 2-chamber (2C) view, and L the shortest superior-
inferior diameter measured in 4C (D3) and 2C (D4) views
(Figure 1). All these measurements were indexed to body
surface area.
TEE images were acquired with a 6 T phased array mul-
tiplane transoesophageal probe (2.9–7.0 MHz). The LA
and LAA were imaged in different tomographic planes to
detect the presence of LAA thrombus and SEC. LA
thrombus was diagnosed by the presence of an echo-
dense mass in the left atrium or the LAA [28]. Spon-
taneous echocardiographic contrast was diagnosed by the
presence of characteristic dynamic smoke-like swirling
echoes in the LA or the LAA, distinct from background
white noise caused by excessive gain [29], and was classi-
fied according to the classification (1 to 4+) proposed by
Fatkin et al. [30]. Dense SEC was defined as grade 3+ or
4+. Left atrial appendage flow velocities were assessed
with a pulsed Doppler sample placed 1 cm from the entry
of the LAA into the body of the LA. Maximum emptying
and filling velocities were estimated from an average of
five well-defined emptying and filling waves. Patients with
maximum emptying and filling velocity ≤20 cm/s were
classified as having low flow velocities.Figure 1 Echocardiographic parameters used to calculate the left atri
D1 - LA AP diameter; D2 - medial–lateral diameter; D3 - superior-inferior diStudy endpoints
The study endpoints were the TEE surrogate markers of
stroke: LAA thrombus, LAA low flow velocities and
dense SEC. The composite endpoint of LA abnormality
(LA ABN) was defined by the presence of at least one of
the previous markers.
Statistical analysis
Statistical analysis was performed using SPSS, version
17.0. Baseline characteristics were described with mean ±
standard deviation for continuous data and counts and
proportions for categorical data. The Kolmogorov-Smirnov
test was used to test the normal distribution of continuous
variables. The Chi-square test, Student’s t-test and non-
parametric equivalent tests were used when appropriate.
P values <0.05 (two-sided) were considered statistically
significant.
A comparative univariate analysis of patients with and
without LA ABN was performed to evaluate potential
differences between the groups regarding demographic,
clinical, echocardiographic and laboratorial parameters.
The discriminatory power of the indexed and non-
indexed LA measurements (AP diameter, area 4C, ellips-
oid volume, 1P area-length volume and 2P area-length
volume) to identify TEE surrogate markers of stroke (LAA
thrombus, LAA low flow velocities, dense SEC and LA
ABN) was evaluated through the receiver operating cha-
racteristic (ROC) curve, which refers to the ability of a
model to assign a higher probability to patients reaching
an endpoint than those who did not reach it. Comparisons
of areas under ROC curves (AUC) were performed bet-
ween LA indexed measurements, using MedCalc for
Windows version 9.2.0.1. A ROC curve subanalysis was
also carried out for patients previously under oral anticoa-
gulation regarding LA thrombus, LAA low flow velocities
or at least one of these two parameters.al volumes. Legend: A1 - LA area in 4C view; A2 - LA area in 2C view;
ameter in 4C view; D4 - superior-inferior diameter in 2C view.
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thod) was performed to identify independent predictors
of TEE surrogate markers of stroke, among the different
methods of LA size quantification and the parameters
included in CHADS2 or CHA2DS2-VASc scores.
Inter- and intra-observer variability was assessed for
the three echocardiographers using a sample composed
of the first 50 patients included in the study: for dense
SEC and LAA thrombus correlations were used; for LA
measurements, we performed a Bland-Altman analysis
using MedCalc for Windows version 9.2.0.1.
Results
Study population
Baseline characteristics of the 500 patients enrolled in this
study are summarized in Table 1. There was a lower preva-
lence of female gender (34.2%). The average CHADS2 and
CHA2DS2-VASc scores were 1.9 ± 1.2 and 3.2 ± 1.7, re-
spectively. Forty point six per cent of patients were pre-
viously medicated with oral anticoagulants and 33.8%
with antiplatelet agents; in 33.8% of patients, one to three
injections of enoxaparin were performed prior to TEE.
The duration of the current atrial fibrillation episode was
estimated to be longer than one year in 26.8% of patientsTable 1 Study population baseline characteristics
Baseline character
Demographics
Age (years) 69 ± 10
Age≥ 75 years 31% (155)
Age 65–74 years 39.8% (199)
Body Mass Index (Kg/m2) 26.6 ± 8.8




Previous Stroke/TIA 14.8% (74)
Congestive heart failure 54.8% (274)
Vascular diseasea 52% (260)
CHADS2 1.9 ± 1.2
CHA2DS2-VASc 3.2 ± 1.7
Pacemaker or ICD 19.6% (98)
Estimated current AF episode duration
≤ 48 hours 7% (35)
< 1 week 19.6% (98)
< 1 month 36% (180)
> 6 months 35.8% (179)
> 1 year 26.8% (134)
Legend: GFR – glomerular filtration rate; ICD - implantable cardioverter defibrillator;
ischaemic attack.
aVascular disease is defined as having at least one of the following: myocardial infa(Table 1). AF was persistent in 73.2% of patients (n = 366)
and long-standing persistent in 26.8% of patients (n = 134).
TEE examinations identified 55 patients (11.1%) with LAA
thrombus, 66 (13.2%) with low LAA flow velocities and
120 (24%) with dense SEC. LA ABN was present in 29.6%
of patients (n = 148).
The sub-analysis of demographic, clinical, echocardio-
graphic and laboratorial characteristics of the study popu-
lation according to the presence or absence of LA ABN is
presented in Table 2. Patients with LA ABN had higher
thromboembolic risk (CHADS2: 2.1 ± 1.1 vs. 1.8 ± 1.2,
p = 0.001; CHA2DS2-VASc: 3.6 ± 1.6 vs. 3.0 ± 1.7, p < 0.001),
were older (70 ± 8 vs. 68 ± 11, p = 0.02), had higher
prevalence of congestive heart failure (65.7% vs. 50.4%,
p = 0.002) and vascular disease (62.8% vs. 47.4%, p = 0.003),
and less frequently a left ventricle ejection fraction ≥55%
(58.8% vs. 79.8%, p < 0.001). They presented higher values
for all LA measurements performed and had longer AF
duration (Table 2). Although patients with LA ABN were
more often anticoagulated (50% vs. 36.6%, p = 0.01), there
was no difference in the prevalence of effective anti-
coagulation (20.9% vs. 20.7%, p = ns) or in the average
INR (1.5 ± 0.7 vs. 1.5 ± 0.8, p = ns) at the time TEE was
performed.istics (n = 500)
Medication previous to TEE
Oral Anticoagulation 40.6% (203)
Antiplatelet agents 46.4% (232)
1-3 doses of enoxaparine 33.8% (169)
Echocardiographic characterization
LA AP diameter (cm) 4.7 ± 0.7
LA area (cm2) 27.6 ± 7.1
LA ellipsoid volume (cm3) 74.1 ± 29.0
LA 1P area-length volume (cm3) 113.8 ± 47.7
LA 2P area-length volume (cm3) 104.1 ± 38.1
LV ejection fraction ≥55% 73.6% (368)
LAA thrombus 11.1% (55)
LAA low flow velocities 13.2% (66)
Dense SEC 24% (120)
LA ABN 29.6% (148)
Laboratorial evaluation
Haemoglobin (g/dL) 13.2 ± 1.8
Platelets (103/μL) 219.7 ± 85.5
INR 1.5 ± 0.8
INR≥ 2.0 20.8% (104)
GFR (mL/min/1.73 m2) 62.4 ± 33.0
INR – international normalized ratio; LV – left ventricle; TIA – transient
rctions, peripheral artery disease, and complex aortic plaque.
Table 2 Sub-analysis of baseline characteristics according
to the presence of left atrial abnormality
Parameter Without LA ABN With LA ABN p
Demographics
Age (years) 68 ± 11 70 ± 8 0.02
Body Mass Index (Kg/m2) 26.8 ± 9 26 ± 8.1 0.4
Female gender 33% (116) 37.2% (55) 0.4
Clinical data
Hypertension 80.8% (284) 84.6% (125) 0.4
Diabetes 21.9% (77) 28% (41) 0.1
Previous Stroke/TIA 13.2% (46) 18.9% (28) 0.1
Congestive heart failure 50.4% (177) 65.7% (97) 0.002
Vascular diseasea 47.4% (167) 62.8% (93) 0.003
CHADS2 score 1.8 ± 1.2 2.1 ± 1.1 0.001
CHA2DS2-VASc score 3 ± 1.7 3.6 ± 1.6 <0.001
Pacemaker or ICD 18.8% (66) 21.7% (32) 0.7
Estimated current AF episode duration
≤ 48 hours 8.5% (30) 3.6% (5) 0.06
< 1 week 24% (84) 9.5% (14) <0.001
< 1 month 40% (141) 26.3% (39) 0.001
> 6 months 31% (109) 47.3% (70) 0.001
> 1 year 22.2% (78) 37.8% (51) 0.001
Echocardiographic characterization
LA AP diameter, (cm) 4.6 ± 0.7 4.8 ± 0.8 0.004
LA area (cm2) 26.4 ± 6.8 30.3 ± 7.1 <0.001
LA ellipsoid volume (cm3) 70.5 ± 28.2 82.1 ± 29.4 0.001
LA 1P area-length
volume (cm3)
106.6 ± 45.9 130 ± 47.7 <0.001
LA 2P area-length
volume (cm3)
97.6 ± 37.6 117 ± 35.9 <0.001
Indexed LA AP diameter,
(cm/m2)
2.4 ± 0.5 2.7 ± 0.4 <0.001
Indexed LA area (cm2/m2) 14.2 ± 4.1 16.9 ± 4.1 <0.001
Indexed LA ellipsoid
volume (cm3/m2)
37.6 ± 16.3 45.3 ± 16.3 <0.001
Indexed LA 1P area-length
volume (cm3/m2)
56.9 ± 24.7 72.3 ± 26.9 <0.001
Indexed LA 2P area-length
volume (cm3/m2)
51.9 ± 20.6 64.8 ± 20.9 <0.001
LV ejection fraction ≥55% 79.8% (281) 58.8% (87) <0.001
Medication previous to TEE
Oral Antiocagulation 36.6% (129) 50% (74) 0.01
Antiplatelet agents 48.8% (172) 40.5% (60) 0.1
1-3 doses of enoxaparine 36.1% (127) 28.3% (42) 0.1
Table 2 Sub-analysis of baseline characteristics according
to the presence of left atrial abnormality (Continued)
Laboratorial evaluation
Haemoglobin (g/dL) 13.3 ± 1.9 13.1 ± 1.6 0.3
Platelets (103/μL) 220.6 ± 91.4 217.5 ± 69.4 0.7
INR 1.5 ± 0.8 1.5 ± 0.7 0.8
INR≥ 2.0 20.7% (73) 20.9% (31) 0.96
GFR (mL/min/1.73 m2) 61.9 ± 33.1 63.8 ± 32.8 0.6
Legend: GFR – glomerular filtration rate; ICD - implantable cardioverter defibrillator;
INR – international normalized ratio; LV – left ventricle; TIA – transient
ischaemic attack.
aVascular disease is defined as having at least one of the following: myocardial
infarctions, peripheral artery disease, and complex aortic plaque.
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stroke on TEE
Figure 2 presents the results of ROC curve analysis of the
different indexed and non-indexed LA measurements for
identifying LAA thrombus, LAA low flow velocities, dense
SEC and LA ABN.
Except for LA AP diameter in identifying LA thrombus,
all other LA measurements showed a good discriminatory
ability in the prediction of the study endpoints (Figure 2).
Indexing to body surface area increased the accuracy of
every LA measurement to recognize each TEE surrogate
marker of stroke (Figure 2).
Taking into account the possible influence of oral antic-
oagulation on dense SEC, a sub-analysis of the discrimin-
atory ability of LA measurements for predicting the other
surrogate markers of stroke (LA thrombus, LAA low flow
velocities or at least one of these two parameters), was car-
ried out for patients previously under oral anticoagulation
(Figure 3). In this subset of 165 patients, LAA thrombus
was found in 21 patients, LAA low flow velocities in 23
patients and at least one of these parameters in 40 pa-
tients. There was a good discriminatory ability of the LA
measurements for identifying LAA low flow velocities in
this sample, though the results were not as consistent for
identifying LAA thrombus (Figure 3).
The most suitable TTE measurements to identify TEE
surrogate markers of stroke
The highest AUC for the prediction of study endpoints
was achieved with indexed LA area 4C for LAA thrombus
(AUC 0.788, CI95% 0.644 – 0.772, p < 0.001), dense SEC
(AUC 0.693, CI95% 0.638 – 0.748, p < 0.001) and LA ABN
(AUC 0.705, CI95% 0.654 – 0.755, p < 0.001). Regarding
LAA low flow velocities, the highest AUC was obtained
with indexed 2P area-length method (AUC 0.737, CI95%
0.664 – 0.810, p < 0.001) – Figure 2.
Generally, indexed LA area 4C and indexed 1P and 2P
area-length methods showed a moderately high discri-
minatory power in the prediction of the study endpoints
and stood out from all the other measurements. ROC
Figure 2 Receiver operating characteristic-curve analysis of indexed and non-indexed left atrial measurements for identifying TEE
endpoints. Legend: AP – anteroposterior; AUC – area under the curve; CI – confidence interval; LA – left atrial; LAA – left atrial appendage;
LA ABN – left atrial abnormality; p – significance level; SEC – spontaneous echocardiographic contrast; 4C – 4-chamber; 1P – single-plane; 2P – biplane.
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reveal a significant difference between them (Table 3).
On multivariate analysis considering the different me-
thods of LA size quantification and the parameters in-
cluded in CHADS2 score, indexed LA area 4C was an
independent predictor of LAA low flow velocities, dense
SEC and LA ABN, while indexed 2P area-length volume
was an independent predictor of LA thrombus (Table 4).
The same analysis with the parameters of CHA2DS2-
VASc score reached similar results, with exception for
dense SEC (Table 4).
On multivariate analysis including the LA volumes
and the CHADS2 score parameters, indexed 2P area-
length volume was an independent predictor of LA
thrombus, dense SEC and LA ABN; Indexed 1P area-length volume was independent predictor of LAA low
flow velocities (Table 5). The same analysis considering
CHA2DS2-VASc score parameters reached similar re-
sults, with exception for dense SEC (Table 5).
A multivariate analysis taking into account LA areas
and CHADS2 or CHA2DS2-VASc score parameters re-
vealed indexed LA area 4C as an independent predictor
of all TEE endpoints (Table 6).
Inter- and intra-observer variability for the different LA
size quantification methods, dense SEC and LAA thrombus
is presented in Table 7.
Discussion
Our results suggest that LA dilation is associated with an
increase in the prevalence of TEE markers of increased
Figure 3 Receiver operating characteristic-curve sub-analysis of left atrial measurements for identifying LAA thrombus, LAA low flow
velocities or at least one of one of these parameters, in patients under previous oral anticoagulation. Legend: AP – anteroposterior;
AUC – area under the curve; CI – confidence interval; LA – left atrial; LAA – left atrial appendage; p – significance level; 4C – 4-chamber; 1P – single-plane;
2P – biplane.
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ently from recognized clinical risk factors. A stronger
association was found for measurements indexed to
body surface area, with the best discriminative ability
obtained with indexed LA area 4C, indexed LA 1P
area-length volume and indexed LA 2P area-length
volume.
This is the first study to date evaluating and compar-
ing the discriminative power of different methods for
LA size measurement in the prediction of markers of left
atrial stasis: LAA thrombus, dense SEC, LAA low flow
velocities and LA ABN.
Predictors of left atrial stasis
The presence of thrombus in the LAA, dense SEC, LAA
low flow velocities and LA ABN are strongly associated
with thromboembolism and adverse outcomes in pa-
tients with AF [22-24]. Accordingly, TEE has been rec-
ommended to evaluate the risk of thromboembolism
previous to procedures such as cardioversion or catheter
ablation [31,32].In this study population, the presence of LA ABN was
associated with longer AF duration and higher thrombo-
embolic risk assessed by CHADS2 and CHA2DS2-VASc
scores, due to a higher prevalence of recognized thrombo-
embolic risk factors such as older age, heart failure, vascu-
lar disease and systolic dysfunction (Table 2). LA ABN
was also associated with a larger left atrium, independently
of the used method (Table 2). On multivariate analysis,
indexed LA area 4C and indexed 2P area-length volume
were predictors of LA ABN (Tables 4, 5 and 6). It is now
established that LA enlargement is not considered part of
the normal aging process, but related to underlying patho-
logical processes such as systolic dysfunction, heart failure
or vascular disease.
Left atrial size – an underexplored marker of
prothrombotic risk?
For all evaluated methods, a larger LA was associated
to LA ABN (Table 2). Also, most non-indexed and all
indexed measurements showed moderate accuracy
in the prediction of all thromboembolic risk markers













LAAT p = 0.08 LAAT p = 0.910 LAAT p = 0.122 LAAT p = 0.082
DSEC p = 0.1 DSEC p = 0.231 DSEC p = 0.248 DSEC p = 0.389
LFV p = 0.024 LFV p = 0.358 LFV p = 0.127 LFV p = 0.245
LA ABN p = 0.046 LA ABN p = 0.187 LA ABN p = 0.154 LA ABN p = 0.249
Indexed LA Area 4C
LAAT p = 0.037 LAAT p = 0.888 LAAT p = 0.795
DSEC p = 0.451 DSEC p = 0.466 DSEC p = 0.358
LFV p = 0.064 LFV p = 0.061 LFV p = 0.069
LA ABN p = 0.212 LA ABN p = 0.186 LA ABN p = 0.242
Indexed LA
elipsoide volume
LAAT p = 0.010 LAAT p = 0.033
DSEC p = 0.722 DSEC p = 0.997
LFV p = 0.314 LFV p = 0.472
LA ABN p = 0.565 LA ABN p = 0.805
Indexed LA 1P
area-length volume
LAAT p = 0.766
DSEC p = 0.608
LFV p = 0.519
LA ABN p = 0.633
Indexed LA 2P
area-length volume
Legend: AP – anteroposterior; DSEC – dense spontaneous echocardiographic contrast; LA – left atrial; LA ABN – left atrial abnormality; LAAT – left atrial
appendage thrombus; LFV - left atrial appendage low flow velocities; p – significance level; 4C – 4-chamber; 1P – single-plane; 2P – biplane.
Table 4 Multivariate analysis including LA measurements and CHADS2/CHA2DS2-VASc parameters for prediction of TEE
surrogate markers of stroke
TEE markers of stroke Independent predictors OR CI95% p
LA measurements + CHADS2 parameters
LAA thrombus • Indexed LA 2P Area-Length Volume 1.026 1.009 - 1.043 0.003
• Previous stroke/TIA 4.080 1.647 – 10.102 0.002
LAA LFV • Indexed LA Area 4C 1.174 1.083 – 1.272 <0.001
Dense SEC • Indexed LA Area 4C 1.090 1.018 – 1.167 0.01
LA ABN • Indexed LA Area 4C 1.114 1.037 – 1.196 0.003
• Congestive heart failure 2.022 1.109 – 3.690 0.02
LA measurements + CHA2DS2-VASc parameters
LAA thrombus • Indexed LA 2P Area-Length Volume 1.028 1.010 – 1.046 0.002
• Previous stroke/TIA 4.071 1.568 – 10.569 0.004
LAA LFV • Indexed LA Area 4C 1.186 1.089 – 1.291 <0.001
Dense SEC • Previous stroke/TIA 2.675 1.158 – 6.180 0.02
• Congestive heart failure 2.308 1.180 – 4.514 0.02
LA ABN • Indexed LA Area 4C 1.106 1.029 – 1.190 0.006
• Congestive heart failure 2.097 1.126 – 3.907 0.02
Legend: CI - confidence interval; LA – left atrial; LAA – left atrial appendage; LA ABN – left atrial abnormality; LFV – low flow velocities; OR – odds ratio;
p – significance level; SEC – spontaneous echocardiographic contrast; TEE – transesophageal echocardiography; TIA – transient ischemic attack; vel – velocities;
4C – 4-chamber; 2P – biplane.
Faustino et al. Cardiovascular Ultrasound 2014, 12:28 Page 8 of 12
http://www.cardiovascularultrasound.com/content/12/1/28
Table 5 Multivariate analysis including LA volume measurements and CHADS2/CHA2DS2-VASc parameters for
prediction of TEE surrogate markers of stroke
TEE markers of stroke Independent predictors OR CI95% p
LA Volumes + CHADS2 parameters
LAA thrombus • Indexed LA 2P Area-Length Volume 1.026 1.009 – 1.043 0.003
• Previous stroke/TIA 4.080 1.647 – 10.102 0.002
LAA LFV • Indexed LA 1P Area-Length Volume 1.022 1.010 – 1.034 <0.001
Dense SEC • Indexed LA 2P Area-Length Volume 1.013 0.999-1.028 0.07
• Congestive heart failure 1.968 1.024 – 3.783 0.04
• Previous stroke/TIA 2.458 1.093 – 5.530 0.03
LA ABN • Indexed LA 2P Area-Length Volume 1.021 1.006 – 1.035 0.005
• Congestive heart failure 2.065 1.134 – 3.758 0.02
LA Volumes + CHA2DS2-VASc parameters
LAA thrombus • Indexed LA 2P Area-Length Volume 1.028 1.010 – 1.046 0.002
• Previous stroke/TIA 4.071 1.568 – 10.569 0.004
LAA LFV • Indexed LA 1P Area-Length Volume 1.023 1.180 – 1.037 <0.001
Dense SEC • Previous stroke/TIA 2.675 1.158 – 6.180 0.02
• Congestive heart failure 2.308 1.180 – 4.514 0.02
LA ABN • Indexed LA 2P Area-Length Volume 1.019 1.005 – 1.034 0.009
• Congestive heart failure 2.133 1.147 – 3.966 0.02
Legend: CI - confidence interval; LA – left atrial; LAA – left atrial appendage; LA ABN – left atrial abnormality; LFV – low flow velocities; OR – odds ratio;
p – significance level; SEC – spontaneous echocardiographic contrast; TEE – transesophageal echocardiography; TIA – transient ischemic attack; vel – velocities;
1P – single-plane; 2P – biplane.
Table 6 Multivariate analysis including LA area measurements and CHADS2/CHA2DS2-VASc parameters for prediction
of TEE surrogate markers of stroke
TEE markers of stroke Independent predictors OR CI95% p
LA Areas + CHADS2 parameters
LAA thrombus • Indexed LA Area 4C 1.119 1.047 - 1.196 0.001
• Previous stroke/TIA 3.977 1.987 – 7.959 <0.001
LAA LFV • Indexed LA Area 4C 1.141 1.075 – 1.211 <0.001
Dense SEC • Indexed LA Area 4C 1.136 1.078 – 1.198 <0.001
LA ABN • Indexed LA Area 4C 1.142 1.083 – 1.204 <0.001
• Congestive heart failure 1.592 1.019 – 2.487 0.04
LA Areas + CHA2DS2-VASc parameters
LAA thrombus • Indexed LA Area 4C 1.133 1.058 – 1.213 <0.001
• Previous stroke/TIA 3.932 1.917 – 8.069 <0.001
LAA LFV • Indexed LA Area 4C 1.139 1.071– 1.212 <0.001
Dense SEC • Indexed LA Area 4C 1.125 1.065 – 1.189 <0.001
• Previous Vascular diseasea 1.930 1.180 – 3.154 0.009
LA ABN • Indexed LA Area 4C 1.147 1.086 – 1.210 <0.001
• Previous Vascular diseasea 1.581 1.010 – 2.474 0.05
Legend: CI - confidence interval; LA – left atrial; LAA – left atrial appendage; LA ABN – left atrial abnormality; LFV – low flow velocities; OR – odds ratio;
p – significance level; SEC – spontaneous echocardiographic contrast; TEE – transesophageal echocardiography; TIA – transient ischemic attack; vel – velocities;
4C – 4-chamber.
aVascular disease is defined as having at least one of the following: myocardial infarctions, peripheral artery disease, and complex aortic plaque.
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Table 7 Inter- and intra-observer variability for the different LA quantification methods, dense spontaneous
spontaneous echocardiographic contrast and left atrial appendage thrombus
Inter-observer variability A vs B A vs C B vs C
LA AP Diameter (mean ± SD,%) 1.05 ± 0.19 1.04 ± 0.2 1.04 ± 0.18
LA Area 4C (mean ± SD,%) 1.03 ± 0.23 1.04 ± 0.24 1.02 ± 0.21
LA Ellipsoid Volume (mean ± SD,%) 1.12 ± 0.36 1.1 ± 0.36 1.08 ± 0.33
LA 1P Area-Lenght Volume (mean ± SD,%) 1.09 ± 0.44 1.11 ± 0.47 1.06 ± 0.41
LA 2P Area-Lenght Volume (mean ± SD,%) 1.05 ± 0.28 1.07 ± 0.28 1.03 ± 0.27
Dense SEC R = 0.797, p < 0.001 R = 0.849, p < 0.001 R = 0.841, p < 0.001
LAA Thrombus R = 0.857, p < 0.001 R =1, p < 0.001 R = 0.857, p < 0.001
Intra-observer variability A B C
LA AP Diameter (mean ± SD,%) 1 ± 0.08 1 ± 0.08 1 ± 0.07
LA Area 4C (mean ± SD,%) 1.01 ± 0.11 1.01 ± 0.09 1.01 ± 0.1
LA Ellipsoid Volume (mean ± SD,%) 1.01 ± 0.1 01.01 ± 0.1 0.98 ± 0.11
LA 1P Area-Lenght Volume (mean ± SD,%) 1.03 ± 0.24 1.02 ± 0.2 1.03 ± 0.22
LA 2P Area-Lenght Volume (mean ± SD,%) 1.01 ± 0.15 1.01 ± 0.15 1.02 ± 0.14
Dense SEC R =0.901, p < 0.001 R =1, p < 0.001 R = 1, p < 0.001
LAA Thrombus R = 1, p < 0.001 R = 1, p < 0.001 R =1, p < 0.001
Legend: LA – left atrial; LAA – left atrial appendage; SEC – spontaneous echocardiographic contrast; 4C – 4-chamber; 1P – single-plane; 2P – biplane.
A, B and C represent the three different echocardiographers.
For LA measurements are presented the results of Bland-Altman analysis, expressed as mean ± SD of the ratio of the measurements in comparison. For dense
spontaneous spontaneous echocardiographic contrast and left atrial appendage thrombus are presented the variability is presented as a correlation.
Faustino et al. Cardiovascular Ultrasound 2014, 12:28 Page 10 of 12
http://www.cardiovascularultrasound.com/content/12/1/28assessed by TEE (Figure 2). Similar results were also
found for identifying LAA low flow velocities or at
least LAA low flow velocities or LAA thrombus in the
subset of patients previously under oral anticoagula-
tion. For predicting LAA thrombus in this subgroup,
the results were not so consistent among the different
LA measurements, however they may have been influ-
enced by the small number of patients (n = 165) and
the limited number of surrogate markers of stroke
(LAA Thrombus: n = 21, low LAA flow velocities: n = 23,
both n = 40) included in this sample.
On multivariate analysis, LA size was predictor of LA
ABN, LAA thrombus, LAA low flow velocities and
dense SEC independently from most thromboembolic
risk factors used in CHADS2 and CHA2DS2-VASc scores
(Tables 4, 5 and 6). These results suggest that LA size
may be used to predict stroke in patients with non-
valvular AF and, eventually, improve thromboembolic
risk stratification of these patients. In one study of 334
patients with AF undergoing transesophageal echocardi-
ography, indexed LA volume was a significant predictor
of LAA thrombus (OR 1.02, p = 0.02) and added incre-
mental predictive value to left ventricle ejection fraction
[33]. Another study demonstrated that LA area 4C asso-
ciated to left ventricular ejection fraction could be used
to identify LAA thrombus, LAA low flow velocities,
dense SEC or LA ABN, and further refine the ability of
CHADS2 and CHA2DS2-VASc scores to identify these
TEE surrogate markers of stroke [34]. However, thediscriminative capability of an isolated LA measurement
to identify TEE surrogate markers of stroke has never
been evaluated.
Due to the wide variety of LA size quantification
methods, it seems important to identify the most suit-
able and accurate method for thromboembolic risk
assessment. When assessing LA size it is crucial to
index results to body surface area, as confirmed by the
observed improvement in AUC with the different
indexed methods in our sample.
The indexed measurements of LA area 4C, LA 1P and
2P area-length volumes stood out among all LA mea-
surements for their moderate to high discriminatory
power in the prediction of LAA thrombus, LAA low
flow velocities, dense SEC and LA ABN (Figure 2), with-
out significant differences between them (Table 3).
Indexed LA area 4C was an independent predictor of all
TEE endpoints (Table 6). Importantly, for dense SEC,
LAA low flow velocities and LA ABN, this predictive
ability was independent of other LA measurements
(Table 4). For LAA thrombus, indexed 2P area-length
volume was a predictor of TEE surrogate markers of
stroke, irrespectively of the other LA measurements
(Table 4). When considered separately from LA area 4C,
the indexed LA area-length volumes also showed a good
predictive ability for TEE surrogate markers of stroke
(Table 5).
LA enlargement is often asymmetrical, as enlargement
in AP axis may be limited by the thoracic cavity, and it
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[11,14]. Thus, LA AP diameter has been considered in-
accurate, while LA areas or volumes assessed by TTE
rely on fewer geometric assumptions. The 2P volume,
using either the area-length or the discs formula, is the
method currently recommended for LA size quantifica-
tion [19]. In our study, this indexed method has also
proved to be one of the most suitable to indicate the
presence of TEE surrogate markers of stroke, yet single-
plane area-length and area 4C methods showed a similar
ability for this purpose.
Russo C and colleagues [13] evaluated single-plane
and biplane methods for the assessment of LA volume
against three-dimensional echocardiography in 527
participants of a community-based Cohort. They found
strong correlations between single- and biplane LA
volume measurements (r = 0.95, p < 0.01), and single-
(r = 0.93, p < 0.01) and biplane (r = 0.93, p < 0.01) area-
length with three-dimensional volumes, although
single-plane method had a suboptimal agreement for
categorical classification. They suggested that single-
plane method could simplify and expedite LA volume
evaluation, but specific cut-off points should be devel-
oped for this method.
Similar results were also found for LA area 4C and
single-plane area-length methods in the study of
Badano LP and colleagues [15], who found an excellent
correlation between LA area 4C (r = 0.94, p < 0.0001),
single-plane volume (r = 0.98, p < 0.0001) and biplane
volume (r = 0.99, p < 0.0001) with volumes determined
by three-dimensional echocardiography. They verified
that the various methods of LA size quantification were
not comparable, with a better agreement for single-
and biplane volume methods, while LA area misled LA
dilatation severity. They concluded that LA area in-
accuracy was due mainly to inappropriate cut-off values
than to the parameter itself. Furthermore, they sug-
gested that the small additional accuracy obtained by
using the biplane instead of the single-plane area–
length method could allow the use of the single-plane
method for routine clinical use [15]. Interestingly,
reference ranges are also not available for indexed LA
area 4C method in the last joint recommendations for
chamber quantification [19].
In our study we found no significant differences when
comparing indexed LA area 4C, LA 2P and 1P area-
length volume for the discrimination of TEE markers of
thromboembolic risk. This may be due to fact that dif-
ferences between methods may be small and our sample
may lack the necessary statistical power to demonstrate
them. Further studies, sufficiently powered to assess this
issue may be needed. However, at present moment there
is no evidence suggesting that one should be preferred
over the others for this specific aim.Limitations
There are several limitations in this study that must be
highlighted. First, this was a single-centre study, whose
sample was not powered for enabling comparisons be-
tween some of the different methods used for assessing
LA size.
Second, at the time of TEE, 40.6% of the study popu-
lation was under oral anticoagulation, which may have
had an impact in the prevalence of LA stasis markers.
However, we believe this study cohort is representative
of the general population of patients with AF and, as
such, we decided not to exclude patients under oral
anticoagulation. Moreover, some of these patients were
not under therapeutic INR values and it is known that
thrombi may arise even under therapeutic INR.
Conclusion
LA enlargement, determined by indexed LA AP diam-
eter, and indexed and non-indexed LA area 4C and vol-
umes, is suitable to identify LAA thrombus, LAA low
flow velocities, dense SEC and LA ABN in patients with
non-valvular AF. The indexed measurements of LA area
4C, single- and biplane area-length volumes are the most
accurate methods for this purpose, and may be used to
stratify thromboembolic risk in these patients.
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